These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24977939)

  • 1. Canavan disease: clinical features and recent advances in research.
    Hoshino H; Kubota M
    Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
    Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.
    Matalon RM; Michals-Matalon K
    Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canavan disease: a monogenic trait with complex genomic interaction.
    Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
    Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
    Baslow MH; Guilfoyle DN
    Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-genetic therapeutic approaches to Canavan disease.
    Roscoe RB; Elliott C; Zarros A; Baillie GS
    J Neurol Sci; 2016 Jul; 366():116-124. PubMed ID: 27288788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
    Surendran S
    Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
    Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
    J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathogenesis of, and pharmacological treatment for, Canavan disease.
    Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
    Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
    Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
    Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mutation in an Egyptian patient with infantile Canavan disease.
    Zaki OK; El Abd HS; Mohamed SA; Zayed H
    Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
    Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
    J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canavan disease: from spongy degeneration to molecular analysis.
    Matalon R; Michals K; Kaul R
    J Pediatr; 1995 Oct; 127(4):511-7. PubMed ID: 7562269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.